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ABSTRACT
The ability of tumors to induce angiogenesis, or new blood vessel
formation, is critical to their growth and spread. As a result, factors which
inhibit angiogenesis are targets for cancer therapy. One anti-angiogenic agent,
TNP 470, is derived from a compound, fumagillin, which induces cell cycle
arrest specifically in endothelial cells. Fumagillin has been shown to inhibit
the action of a metalloprotease, methionine aminopeptidase-2 (MetAP-2),
which is found in both endothelial and non-endothelial cell types. A crystal
structure of MetAP-2 with bound fumagillin has recently been solved, which
suggests that there are several residues of MetAP-2 in close approximation to
fumagillin. These residues may be important in determining specificity of the
drug for this enzyme. It was thus hypothesized that by mutating these
residues using site-directed mutagenesis, it may be possible to generate
mutant versions of MetAP-2 resistant to fumagillin binding. The results
presented here demonstrate that three such mutations, G341D, G341S, H339F
have been identified. These mutations confer resistance to 10 nM, 5nM, and
InM concentrations of fumagillin, respectively, which would normally
inhibit wild type MetAP-2. If endothelial cells expressing these mutations are
resistant to the cell-cycle arrest normally induced by this drug, it constitutes
significant functional evidence that the anti-angiogenic effect of this drug can
be attributed to its specific interaction with MetAP-2.
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INTRODUCTION
Angiogenesis
Angiogenesis can be defined as growth of new microvessels (1). This
process is dependent on the proliferation of capillary endothelial cells. These
cells normally divide very slowly, with turnover times on the order of
hundreds of days, and therefore define a relatively quiescent tissue (2).
However, when stimulated appropriately, these cells can emerge from this
quiescent state and undergo brief periods of rapid division. An example of
this type of angiogenesis occurs in the ovarian follicle, in which there is a
burst of capillary vessel growth which lasts a few days, and is then turned off.
Pathologic angiogenesis occurs when the process of angiogenesis
continues to occur for long periods of time, on the order of months to years.
An example of this process occurs in tumor growth. In 1974, Folkman
hypothesized that in the absence of vascularization, the size and growth of
tumors is limited (3). He suggested that there are several "microtumors"
developing at any given time in the human body, which never develop into
detectable tumors due to lack of adequate supply of oxygen and nutrients. At
some point in tumor development, however, these microtumors develop the
ability to induce the formation of new blood vessels. These new vessels
provide nutrients and oxygen, and act as conduits through which metastases
can spread. Although the exact mechanism is unclear, several studies have
supported this hypothesis (4). As a result, a new target of cancer therapy has
been the development of agents which can selectively inhibit this angiogenic
process, thereby returning microtumors to their equilibrium resting state.
This is the fundamental goal of anti-angiogenic cancer therapy.
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Fumagillin/TNP-470
In 1990, it was shown by D. Ingber that a fungal contaminant,
Aspergillus fumigatus fresenius, inhibits growth of capillary endothelial cells
in culture (5). The active compound secreted by the fungus is fumagillin
(Figure

1).

A
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non-toxic

synthetic

Modulator-1470)

has

analog
been

of

fumagillin,

shown

to

AGM-1470

inhibit

capillary

endothelial cell growth at picomolar concentrations in vitro (6). The clinical
preparation is synthesized by Takeda Pharmaceutical Company and called
Takeda Neoplastic Product-470, or TNP-470. TNP-470 is a more potent
inhibitor of capillary endothelial cell division

than fumagillin and has

demonstrated little toxicity in studies to date (7-10). Systemic administration
of TNP-470 have been shown to inhibit tumor growth in mice, rats, and
rabbits, although in vivo tumor inhibition requires higher concentrations
than in vitro cell culture assays (11-14).
The exact mechanism of action of TNP-470 is unknown. However, it
has been shown to specifically induce arrest of endothelial cells in the late G[
phase of the cell cycle (15). TNP-470 results in the inhibition of the
retinoblastoma gene product phosphorylation as well as inhibition of cyclin
dependent kinases cdk2/4 and expression of cyclins E and A (15). It is known
that the late G] arrest is not a result of perturbation of early signaling events,
since addition of the agent 3 hours after stimulation with growth factor still
results in full arrest (15).
Initial explorations into the mechanism of action of TNP-470 revealed
that the agent binds covalently to an enzyme, Methionine Aminopeptidase-2
(MetAP-2) , which was initially identified biochemically based on its ability to
cleave the amino-terminal methionine residue from peptide substrates (16).
This enzyme is found in both endothelial and non-endothelial cells (17),
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although the inhibition of the cell cycle has been shown to exhibit specificity
to endothelial cell types for unknown reasons (18).

Methionine Aminopeptidases
Members of the methionine aminopeptidase (MetAP) family are cobalt
dependent metalloproteases, which function in the selective cleavage of
methionine from the amino terminus of peptides and proteins in a nonprocessive manner (19). Based on sequences comparisons, it has been
proposed that two distinct MetAP families exist, MetAP-1 and MetAP-2 (20).
Studies in isogenic yeast strains differing only in the presence or absence of
functional MetAP-1 or MetAP-2 have shown that fumagillin binds selectively
to, and specifically and irreversibly inhibits, MetAP-2 in vivo (16).
There is evidence that MetAP-2 serves a critical role in cell growth in
addition to its housekeeping function. Experiments in S. cerevisiae have
shown that deletion of either MetAP-1 or MetAP-2 results in viable, slowgrowing yeast. Deletion of both genes results in a lethal phenotype (21).
MetAP-2 expression has been shown to correlate with cell growth. In
quiescent cells, MetAP-2 levels are below the level of detection using standard
immunologic methods. Upon addition of a mitogen, the protein levels
increase greatly (22). MetAP-2 has also been identified as a 67kDa protein
associated with cell cycle factor eIF-2, and partially reverses protein synthesis
inhibition mediated by phosphorylation of eIF-2 in vivo (23). It is unlikely
that TNP-470 cell cycle arrest is due to interruption of this interaction, because
the general protein synthesis inhibition that would result is not compatible
with the 7-fold induction in E-selectin protein levels that is seen upon TNP470 addition (24).
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Crystal Structure of Fumagillin-bound MetAP-2
Although the binding to and inhibition of MetAP-2 by fumagillin is
well documented, this does not constitute satisfactory evidence that the antiangiogenic property of fumagillin is due to this interaction. In order to
further define the interaction, a 1.8 angstrom resolution crystal structure has
recently been solved for human MetAP-2 alone and bound to fumagillin (25).
The crystallographic data has shown that human MetAP-2 has a central [3
sheet with an active site located approximately at the center of its concave
face. Two pairs of a-helices and a short COOH-terminal tail cover the sheet's
concave face (Figure 2). The active site is a deep pocket with two cobalt
molecules at its base, and another pocket that presumably serves as the
specificity pocket for the amino-terminal methionine side chain of neutral
substrates. Reorientation of the Tyr444 side chain and some water molecules
opens this pocket to solvent. This Tyr444 residue is completely conserved in
the MetAP-2 family across species.

Molecular Interactions Between MetAP-2 and Fumagillin
The irreversible inhibition of MetAP-2 by fumagillin is the result of a
covalent bond formed by an imidazole nitrogen atom of His231 of MetAP-2,
and the carbon of the spirocyclic epoxide of fumagillin (16). His231 is believed
to be important for the catalytic activity of the enzyme, as an electrophile in
an acid-base catalytic triad. The residue does not move significantly with this
bond formation, as its nucleophilic imidazole is perfectly positioned to bond
with the methylene of the epoxide. The only molecule that moves upon
fumagillin binding of MetAP-2 is His339, which rotates its side chain to avoid
close contacts with fumagillin (Figure 3). These amino acid residues are
therefore critical to fumagillin binding. In addition, several residues are
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identified by this crystal structure which are in close approximation to bound
fumagillin. These residues include Tyr444, Phe219, lle338, and His331 (Figure
4). These residues form hydrophobic interactions with the molecule in the
deep pocket near the active site of the enzyme. Additionally, the long
unsaturated side chain of fumagillin is directed out of the binding pocket and
makes two hydrophobic contacts with Leu328 and Leu447, both of which are
conserved within the MetAP-2 family (Figure 5) (25).

Relevance of Crystallographic Data
The crystal structure of MetAP-2 bound to fumagillin has allowed
careful analysis of the active site and the deep pocket located near the active
site. Using this information, it may be possible to identify those residues
which are essential in creating a localized environment in the enzyme which
is amenable to the binding of fumagillin. Using a rational approach based on
these data, an attempt may be made to alter these putatively critical residues
of MetAP-2 in order to decrease the affinity with which fumagillin binds the
enzyme. MetAP-2 mutations made using this approach may be useful as an
initial step in the clarification of the exact mechanism of fumagillin induced
cell cycle arrest in endothelial cells. Specifically, MetAP-2 mutations that
allow cell viability but have reduced affinity for fumagillin may be tested for
the response to a known inhibitory concentration of fumagillin in an
endothelial cell system. Demonstration of a reduced potential of fumagillin to
induce cell cycle arrest would suggest that MetAP-2 is a critical point in the
molecular anti-angiogenic mechanism of the drug. Further clarification of the
role of MetAP-2 in the cell may then allow generation of more potent antiangiogenic compounds which may prove clinically useful.
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Summary
Fumagillin and its derivatives are potent anti-angiogenic compounds.
It has been shown that these molecules bind and inhibit an enzyme
Methionine Aminopeptidase-2, a cobalt metalloprotease. There are two
members of the Methionine Aminopeptidase family, MetAP-1 and MetAP-2
that exist in both endothelial and non-endothelial cell types. Fumagillin has
been shown to bind and specifically inhibit MetAP-2. MetAP-2 is thought to
be responsible for the cleavage of the amino-terminal methionine of proteins
and peptides in a non-processive manner. However, in addition to this
housekeeping role, MetAP-2 plays an ill-defined, yet critical role in the
progression of the cell cycle; cells require either MetAP-1 or MetAP-2 for
survival. It is unclear how the functions of MetAP-2 are related. A crystal
structure of fumagillin bound to MetAP-2 has allowed a rational analysis of
the molecular interactions that the molecule makes with the enzyme. The
objective of this study is to determine whether the affinity for fumagillin
binding to MetAP-2 can be decreased or eliminated by manipulation of these
residues, without destroying the catalytic activity of the enzyme. By
demonstrating that mutations can be made in MetAP-2 which decrease the
affinity of fumagillin binding, a system can be developed in endothelial cells
to test whether these mutations affect the anti-angiogenic properties of the
drug. If these properties are indeed altered by mutations in MetAP-2, it
constitutes significant evidence that the binding of fumagillin to MetAP-2 is a
critical point in the molecular mechanism of the molecule's anti-angiogenic
property. Thus this initial study may provide a starting point from which
future detailed studies into the molecular mechanism of fumagillin action
may be attempted. A detailed knowledge of the anti-angiogenic mechanism
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may provide a framework generation of more potent, and highly clinically
relevant anti-angiogenic agents.

Abraham, John

Page 11

PURPOSE OF STUDY AND HYPOTHESIS
The purpose of this study is to identify mutations in the MetAP-2 gene
that interfere with the binding of the anti-angiogenic agent fumagillin to this
enzyme. Given that yeast require either MetAP-1 or MetAP-2 for growth, a
yeast null Met-AP-1 strain (AMetAP-1) relies on functional MetAP-2 for
growth. Fumagillin binds to and completely inhibits MetAP-2. Thus, a
imitation that interferes with the binding of fumagillin to MetAP-2 is any
mutation in MetAP-2 that allows a AMetAP-1 yeast strain to grow in an
inhibitory concentration of fumagillin. That is, a mutation in MetAP-2 that
rescues AMetAP-1 yeast from growth arrest when exposed to an inhibitory
concentration of fumagillin must interfere with the binding of fumagillin to
MetAP-2.
The null hypothesis is that the affinity with which fumagillin binds to
MetAP-2 cannot be decreased by identifying and mutating critical residues in
the MetAP-2 enzyme using a rational approach.
In order to test this hypothesis, the following specific aims are
completed:
1. Identification of mutations which are likely to interfere with binding
2. Generation of the chosen mutations
3. Incorporation of mutation into yeast strain
4. Testing mutant yeast strain for ability to grow in an inhibitory
concentration of fumagillin.
Given the design of this study, the null hypothesis can be rejected by
the identification of a mutation in MetAP-2 which allows yeast growth in the
presence of fumagillin at an otherwise inhibitory concentration.
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MATERIALS AND METHODS
All experiments described below, including production of all reagents,
were designed and performed by the author.

Molecular modeling and selection of desired mutations
Potential mutations were chosen by careful analysis of the crystal
structure of fumagillin bound to MetAP-2. These potential mutations were
modeled in MetAP-2 on a Silicon Graphics workstation running the O
Graphics Molecular Modeling Program. The computer model was studied to
predict the effect of the mutation on fumagillin binding. Mutations which
appeared to cause steric hindrance thereby making fumagillin binding more
difficult were chosen for use in the experiment. There is, however, currently
no method of accurately predicting the impact of a given mutation in a
protein to a binding partner. Thus, the information gleaned from the
molecular modeling described here was simply used as a guideline for
mutation selection, along with the crystal structure of the drug-enzyme
complex.

Site directed mutagenesis
Mutations were made in the MetAP-2 enzyme by using site-directed
mutagenesis, as described in the Stratagene QuickChange Site-Directed
Mutagenesis Kit (Figure 6). This method involves the following steps:
1. Preparation and synthesis of PCR Primers and wild type template
2. PCR generation of Mutants
3. Isolation of mutation
4. Confirmation of mutation
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1. PCR Primers and wild type template
Primers containing the desired mutation flanked by wild type sequence
were synthesized by the Keck Oligonucleotide Facility at Yale University.
Primers were designed using guidelines of 25-40mers with >50% GC content,
and a melting temperature, (Tm) >65°C (26). Desired mutations were located as
close to the center of the primer as possible. Primers were synthesized in both
forward and reverse orientations to allow annealing to either strand of the
template DNA (Figure 7). In cases where multiple codon choices were
available for a single amino acid given the degeneracy of the genetic code, the
codon which is most frequently found in yeast to code for the intended amino
acid was chosen, as reported in Current Protocols in Molecular Biology. The
template plasmid pSE319 is a high-copy episomal plasmid which contains the
entire wild type yeast MAP-2 sequence in addition to a replication origin, a trp
gene, allowing yeast transformed with this plasmid to grow on tryptophan
dropout plates, and an amp resistance gene, allowing for selection on
ampicillin plates. Template DNA was isolated from archived bacteria using
Qiagen QiaSpin Miniprep Kits.

2. PCR Generation of mutant
In order to achieve optimal ratios of template to primer, each PCR
reaction was carried out using three different quantities of template: 6 ng, 12
ng, 18 ng. Template was added to a reaction mix containing: lOmM dNTP,
PCR reaction buffer (Stratagene), 125ng forward primer, 125 ng reverse
primer, H20 for a final volume of 50 |iL. 1U PFU Turbo (Stratagene) was
added to each tube. PCR was carried out in a MJ Research PCR machine using
the following program:
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Step 1.

95°C

30 sec

1 cycle

Step 2.

95°C

30 sec

16 cycles

55°C

60 sec

68°C

15 minutes

Step 3.

1 cycle

3. Isolation of mutant DNA
Newly synthesized mutant DNA was isolated using the restriction
endonuclease Dpn I (New England BioLabs). This enzyme is a frequent
cutting restriction endonuclease which is highly specific for methylated DNA.
This allows the enzyme to preferentially cut the methylated template DNA,
while sparing the newly synthesized, unmethylated mutant gene. Restriction
endonuclease reactions were performed by adding 1U of Dpn I directly to PCR
reaction tube, gently mixing, and incubating for 1 hour at 37°C.

4. Confirmation of mutation
After digestion, 5 mL of sample was drawn from each reaction tube and
loaded on a 0.9% agarose gel containing ethidium bromide. A standard lkb
marker was used. Wild type pSE319 was used as a positive control. DNA from
the positive reactions was sent to the Keck Oligonucleotide Facility at Yale
University for sequencing and confirmation of incorporation of the desired
mutation. Plasmids which were identified as carrying the desired mutation
were used to transform a competent bacterial cell line (DH5a), using

the

following standard bacterial transformation protocol to provide a renewable
source of plasmid.
Bacterial Transformation Protocol
Defrost frozen host cells in ice for 20 minutes
Add PCR mix into tube and incubate 15 minutes on ice
Heat shock host cells at 42°C for 45 seconds
Return to ice for 20 minutes
Add lmL LB medium to mix
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Incubate at 37°C with shaking for 45-60 minutes
Briefly centrifuge mixture and pour off supernatant
Resuspend pellet in small remaining volume of LB
Plate on LB/carbenicillin (50 mg/mL) plate
Incubate for 16-20 hours at 37°C

Yeast transformation
Yeast require either MetAP-1 or MetAP-2 for viability. In order to
exploit this requirement, a yeast null MetAP 1 strain (AMetAP-1) was used for
transformation. This strain is S. cerevisiae strain W303 (MATa/MATa ade2l/ade2-l his3-ll,15/his3-ll,15 Ieu2-3,112/leu2-3,112 ura3-l/ura3-l trpl-l/trpl1 canl-100/canl-100) containing mapl::HIS3 disruption. Plasmids containing
the desired mutant MetAP-2 gene were used to transform the AMetAP-1 yeast
strain using the following standard Lithium Acetate yeast transformation
protocol. Selection for transformants is accomplished by allowing the yeast to
grow on tryptophan dropout plates. Since the vector harbors the tryptophan
selection

marker,

yeast

that

grow

on

these

plates

are

confirmed

transformants. Single colonies are allowed to grow on these plates and are
then selected for the viability assay.
Yeast Lithium Acetate Transformation protocol
Grow AMetAP-1 strain in YPD medium for 20-24 hours at 30°C
Use 3mL saturated culture per transformation, transfer to Eppendorf
tube
Add lOmL per transformation salmon sperm carrier DNA
Add 10 mL plasmid
Vortex gently to mix
Add 500mL transformation solution (100 mM Lithium Acetate, 40%
PEG)
Invert to mix
Incubate at room temperature for 30 minutes
Heat shock at 42°C for 12 minutes
Briefly centrifuge and pour off supernatant
Resuspend pellet in small remaining volume
Plate on tryptophan dropout plate
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Incubate 30°C for 4-6 days

Selection of fumagillin resistant transformants
Single colonies were picked from confirmed transformants from
standard tryptophan dropout plates. These single colonies were then plated
onto tryptophan dropout plates containing various concentrations of
fumagillin: 0.2nm, lnm, 5nm, lOnm. The plates were allowed to incubate at
30°C for 4-7 days and were monitored for growth. Wild type S. cerevisiae was
used as a positive control on each plate, because it has a functional MetAP-1,
which allows it to grow at all the test concentrations of fumagillin used in the
study. AMetAP-1 yeast strain was used as a negative control on each plate,
because it carries wild type MetAP-2, which is fully inhibited at all test
concentrations of fumagillin used in the study.
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RESULTS
Rational Approach to Mutation Selection
The initial objective in this study was to select a set of mutations in the
MetAP-2 enzyme that might have the potential to reduce its binding affinity
to fumagillin. This type of prediction can only be speculative; there is no
current method for modeling a protein-protein interaction with

100%

accuracy. Several amino acid residues in the enzyme were chosen for
mutation. These residues are: His339, Phe219, Tyr444, Gly341(Figures 3,5). The
His339

residue

was

chosen

for

mutation

because

of

the

important

conformational change that occurs at this residue upon fumagillin binding:
the imidazole side change swings out of the way to accommodate fumagillin
binding (25). It was thought that replacement of this residue with an amino
acid which has a bulky side chain that would not be able to change
conformation might hinder fumagillin binding. The mutation H339F was
therefore chosen as a study variable. (All mutations are notated using the
standard one-letter amino acid code notation for the wild type amino acid,
followed by the position in the protein sequence, followed by the one-letter
code for the amino acid that was substituted in

the mutant.

For examle,

H339F indicates that Histidine at position 339 in the wild type MetAP-2 gene
was

substituted

to

Phenylalanine

in

the

mutant.)

Additionally,

the

movement of this histidine imidazole side chain is allowed by the existence
of a glycine residue, Gly341. By virtue of lacking a carbon containing side
chain, this glycine residue ostensibly provides no additional steric resistance
to the movement of the FIis339 side chain. For this reason, Gly341 was also
chosen for mutation to several bulky residues: G341D, G341S, G341V, G341A,
G341H.
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The deep pocket, thought to be a specificity pocket, situated next to the
active site of the enzyme may be important in discriminating the amino
terminal methionine of the natural substrates of this enzyme. This pocket
contains two residues, Phe219 and Tyr444, which were also chosen for
mutation (Figures 3,5). These molecules are in particularly close proximity to
fumagillin as demonstrated by the crystal structure, and form the mouth of
the specificity pocket. The reactive epoxide of fumagillin, which forms the
eventual covalent bond with MetAP-2, is contained in a side chain of
fumagillin which protrudes into this specificity pocket. This occlusion of the
pocket by mutations in these residues may hinder binding of the molecule as
well. Additionally, Tyr444 is conserved in the MetAP-2 family across species,
yet an analog is absent in the MetAP-1 family, which may explain some part
of the inability of fumagillin to bind MetAP-1 (25). The mutations chosen
were F219W, F219I, Y444W, Y444I.

Site-directed mutagenesis
Chosen mutations were made in the desired amino acid positions
using site-directed mutagenesis. The PCR products of the desired mutations
were run on an agarose electrophoresis gel for evidence of a PCR product. In
those experiments that a product was seen, the PCR product was sent for
sequencing for confirmation of the desired mutations. Desired sequences of
all mutations were confirmed before transformation into AMetAP-1 yeast.

Fumagillin Growth Assay
The simplest way to determine whether the binding of fumagillin was
functionally decreased as a result of the test mutation was to grow the yeast
transformed with the desired mutation on test plates containing varying
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concentrations of fumagillin. The concentrations used in this study were 0.2
nM, 1 nM, 5nM, 10 nM. These values were chosen because they represent a
range of concentrations which is known to inhibit growth of AMetAP-1 yeast
strain while remaining non-toxic to wild type yeast. The results are shown in
Figure 8. These results demonstrate three mutations, G341D, G341S, and
H339F, which are resistant to lOnM, 5nM, and InM concentrations of
fumagillin, respectively.
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DISCUSSION
Methionine Aminopeptidase-2 plays an important yet undefined role
in the cell cycle of endothelial cells. Evidence exists which supports MetAP-2
as a binding target of the anti-angiogenic agent fumagillin. It is unclear,
however,

how

this

interaction

leads

to growth arrest specifically

in

endothelial cells. MetAP-2 is known to have a housekeeping role in the cell
which involves cleavage of the amino terminal methionine from many
proteins and peptides. Biologically plausible mechanisms exist by which
interruption of this function may lead to cell arrest, and evidence that either
MetAP-1 or MetAP-2 function is required for cell survival lends additional
support to this hypothesis. The N-end rule proposed by Varshavsky, et al.
states that the stability of a cellular protein is determined in part by the
penultimate amino-terminal residue (27). Thus MetAP-2 may play a role in
regulating the stability of proteins. Alteration of the stability of a critical
protein which is required for progression through the cell cycle may lead to
arrest or growth dysregulation. Furthermore, MetAP-2 plays an important
role in protein myristoylation. The covalent attachment of myristic acid to a
glycine residue occurs in several important cell signaling proteins, such as
certain tyrosine kinase family members, and cyclic AMP-dependent kinase,
after the cleavage of the amino terminal methionine by a MetAP (28).
Myristoylation has been shown to be required for signaling of several proteins
(29). Thus, interruption of MetAP-2 activity may prevent myristoylation of
some key signaling protein in endothelial cells which leads to growth arrest.
An alternate explanation for fumagillin activity specifically on
endothelial cells is that there is some other interaction in these cells which
has not yet been demonstrated that is responsible for growth arrest. Given
that MetAP-2 is a housekeeping enzyme which potentially binds many targets
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in the cell, it is reasonable to question whether the molecular mechanism for
the anti-angiogenic property of fumagillin is indeed related to its binding to
this enzyme. The covalent bond formed between fumagillin and MetAP-2
argues against a non-specific binding, but the drug may have some other
important consequences in

the cell which

leads to growth arrest in

endothelial cells, independent of its binding to MetAP-2. The objective of this
study was to provide a starting point for demonstrating that the antiangiogenic property of fumagillin is mediated through its binding to MetAP2. The first step in this process was to determine whether the affinity with
which fumagillin binds to MetAP-2 could be decreased by mutation of the
enzyme.
The approaches to determining whether MetAP-2 could be mutated to
decrease its affinity for fumagillin include: 1. a rational approach, in which
the molecular structure of the enzyme is studied for amino acids whose
mutation would likely provide resistance for drug binding, or 2. a random
approach, in which many mutations are made throughout the enzyme, and
the viable mutations are selected and tested. In order to study the binding of
fumagillin to MetAP-2, a rational approach was used. The concept of rational
drug design involves carefully studying the structure of a molecule, and
making only those changes which, based

on

that structure, have a

scientifically plausible reason for attaining the desired goal. In this study,
amino acid residues were changed based on either: 1. their proximity to
relatively

inflexible

regions

of

the

fumagillin

molecule

or

2.

their

determination of a specificity region of the enzyme as predicted by the crystal
structure, with the intention of creating steric hindrances that decreased the
affinity of

the

molecule

for the enzyme which could

not easily be

compensated for by conformational change in the molecule. Likewise selected
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residues were mutated to either large, inflexible, or polar amino acids to
increase the chances of providing steric hindrance (such as phenylalanine,
isoleucine, tryptophan, histidine, aspartic acid, and others).
The benefit of this type of approach is that significant results may be
achieved using a relatively small number of mutations, and those results
have a plausible biologic explanation for achieving the desired goal. The
drawback of this approach is that successful mutations which achieve the
desired goal may be missed, because it would have been impossible to predict
the effect those mutations would have had.
It was expected at the outset of this project that the binding between
MetAP-2 and fumagillin would be impossible to block completely given the
highly stable covalent bond that is formed between the reactive epoxide of
fumagillin and His231 of MetAP-2. Furthermore, this residue is thought to be
critical to the catalytic activity of the enzyme, as an electrophile in an acid-base
catalytic triad. Thus, mutation of this residue could potentially destroy the
catalytic activity of the enzyme, but the covalent bond formed by this residue
makes it unlikely that fumagillin binding can be blocked completely using
other mutations in the enzyme. Flowever, a mutation which is found to
decrease the affinity of fumagillin for MetAP-2, while not completely blocking
its binding, would still prove useful in an endothelial cell system designed to
study the relationship of fumagillin's binding to MetAP-2 and its antiangiogenic property. That is, a clear decrease in anti-angiogenic potential of
fumagillin associated with a mutation in an endothelial cell MetAP-2 known
to decrease the affinity of fumagillin binding would conclusively demonstrate
that the drug's mechanism is mediated via its binding to this enzyme.
In order to select potential mutations for testing, the crystal structure of
MetAP-2 bound to fumagillin was carefully studied. There are features of the
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fumagillin binding

site

which

prompted

consideration

for

mutation

selection. The first is the active site of the enzyme. The active site is formed by
a deep pocket in the molecule with two cobalt molecules at its base.
Additionally, there is a completely covered side pocket that may serve as a
specificity pocket for the amino-terminal methionine side chain of the
enzyme's natural substrates. This specificity pocket contains many residues
which come into close proximity with fumagillin upon its binding to the
enzyme.

These include, but are not limited to Tyr444, His339, and Phe219

(Figures 3,5). These residues were chosen for mutation based on these close
hydrophobic contacts, and the fact that they were not known to be critical for
the enzyme function. The mutations chosen were F219I, F219W, Y444I,
Y444W.
The second feature of the drug-bound enzyme that was of interest was
the residue FIis339. This is the only residue in the enzyme which undergoes
significant motion upon fumagillin binding (25). The imidazole side chain of
this residue rotates upon fumagillin binding to avoid close contacts with
fumagillin. It was thought that substitution of an amino acid containing a
side chain less able to perform this rotation might be a useful mutation.
Mutation to phenylalanine was thus attempted. Additionally, there is a
glycine residue, Gly341, which is positioned behind His339, which potentially
provides space to accept the rotation of the His339 side chain upon fumagillin
binding due to its lack of a side chain. It was believed that replacement of this
residue with a bulkier residue might also inhibit the rotation of FIis339 and
therefore decrease fumagillin binding affinity. The mutations chosen were
thus H339F, G341S, G341V, G341A, G341D, G341H.
In order to generate the chosen mutations in the yeast MetAP-2 gene, a
site

directed

mutagenesis

approach

was

used.

In

this

approach,

a
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oligonucleotide containing the desired mutation is synthesized, with several
bases of wild type sequence flanking it on either side. This oligonucleotide,
typically a 40-50mer synthesized in both forward and reverse orientations, is
used as a primer for a PCR, using the wild type gene contained in a plasmid as
a template. After several successive rounds of PCR, a plasmid containing the
desired mutation is generated. The wild type DNA is then digested using a
frequent cutting endonuclease which is highly selective for methylated DNA.
In this fashion, the newly synthesized, non-methylated DNA is spared, while
the template plasmid, which had been harvested from bacterial culture and
thus methylated, is destroyed (Figure 6). Representative samples of successful
PCR reactions, as demonstrated by the appearance of a band at the expected
molecular weight on an agarose gel, were then selected and sequenced for
confirmation of incorporation of the correct mutation.
Confirmed mutants were then used to transform a AMetAP-1 yeast
strain. Use of this strain enabled the simplification of the assay for fumagillin
binding. Given that yeast are dependent on either functional MetAP-1 or
MetAP-2 for growth, a AMetAP-1 strain is dependent entirely on functional
MetAP-2. Thus, a simple growth assay can be used to test the effect of the test
mutations on fumagillin binding. That is, when MetAP-2 is bound and
inhibited by fumagillin, the yeast strain will no longer grow, resulting in a
lack of visible colonies on a fumagillin plate. In cases where the mutated
MetAP-2 is more resistant to binding than wild type, a higher concentration
of fumagillin is required to arrest the yeast strain, resulting in visible colonies
on fumagillin plates at concentrations that would inhibit growth of the wild
type strain. In the theoretical case in which fumagillin binding is totally
blocked by a test mutation, the yeast strain should grow on plates any
concentration of fumagillin. The concentrations used for experimentation in
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this study were 0.2nM, InM, 5nM, and lOnM. These concentrations have been
shown previously in the Crews Laboratory to inhibit growth of AMetAP-1
yeast containing wild type MetAP-2.
Figure 8 shows the results from the initial test mutations. Seven of the
ten attempted mutations displayed no resistance to growth inhibition by
fumagillin. It is expected that these mutations which are designed to increase
steric hindrance of fumagillin binding may be compensated for by small shifts
in the conformation of either the protein or the drug molecule. There is no
current means of accurately predicting this type of small conformational shift.
Test mutations G341D, G341S and H339F displayed resistance to growth
inhibition by

fumagillin

above

wild

type

at

lOnM,

5nM

and

InM,

respectively. The decreased potency of fumagillin in these cases can be
attributed to decreased affinity of binding due to steric limitations imposed by
the test mutation, since this is the only variable changed with respect to wild
type. AMetAPl yeast containing wild type MetAP-2 did not grow at 0.2nm,
InM, 5nM, or lOnM concentration of fumagillin, confirming that these
concentrations fall within a range that fully inhibits wild type MetAP-2. The
findings presented here confirm the hypothesis that generation of specific
mutations in MetAP-2 can interfere with fumagillin binding.
The results presented in this study demonstrate that it is possible to
interfere to some extent the binding of fumagillin to MetAP-2. Although it
has not been possible in this study to completely block binding of fumagillin
to MetAP-2, this may be due in part to the highly stable interaction that is the
result of the formation of a covalent bond between the enzyme and the
reactive epoxide of the drug. Flowever, the significance of the mutations that
have been found to decrease binding affinity is in providing a basis for testing
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the relationship between the binding of fumagillin to MetAP-2 and its antiangiogenic potential.
The next experiment that needs to be done to this end is the stable
incorporation of the mutations described above into an endothelial cell line.
By overexpressing a fumagillin resistant MetAP-2 mutant in an endothelial
cell line, a link can be established between the anti-angiogenic property of the
drug and its binding to this enzyme. That is, if endothelial cells can be rescued
from fumagillin-induced growth arrest by a mutation in MetAP-2 that is
known to decrease fumagillin binding, it would be clearly demonstrated that
the anti-angiogenic property of fumagillin is mediated through its interaction
with the enzyme.

This would exclude the possibility that the specific actions

of fumagillin on endothelial cells relies on some other function of the drug
in endothelial cells that is different that its action in most cells, its interaction
with MetAP-2. Initial attempts were made to introduce this mutation into a
Bovine Aortic Endothelial Cell

(BAEC) line using standard methods,

but

these attempts have been thus far unsuccessful. Alternate methods are
currently under consideration to accomplish this goal.
Other experimentation that could prove useful in the framework of
this experiment include the combination of several successful single
mutations to generate a set of mutations which together result in increased
effectiveness at blocking fumagillin binding. Initial experiments to this end
were performed, but none showed any benefit above the single mutations.
Other combinations may, however, prove useful. Additionally, the His231
residue of the enzyme can be mutated. This residue is responsible for the
formation of the covalent bond between fumagillin and MetAP-2 and is
thought to be a critical residue in the catalytic mechanism of the enzyme.
Although it is likely that mutation of this residue will result in a non-
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functional enzyme, confirmation of this by generation of this mutation
would complete this study.
The significance of the data presented in this study lie mainly in that
they provide a basis for which future significant research can be conducted. As
described previously, the mutations which have been shown to be effective in
reducing the binding of fumagillin to MetAP-2 can now be transferred to an
endothelial cell system to determine whether the anti-angiogenic effects of
the drug are mediated by its interaction with this enzyme. This is a critical
piece of information in the delineation of the molecular mechanism of this
drug. A clear understanding of the molecular mechanism of this antiangiogenic agent may allow the generation of more potent, less toxic agents,
by identifying new molecular targets. Understanding the molecular basis of
this growth pathway in endothelial calls may also provide valuable insights
to basic endothelial cell biology, which can have important ramifications to
tumor and vascular biology.
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Structure

Compound

Fumagillin

TNP-470
O

O

Figure 1. Molecular structure of fumagillin. The chemical structure of the
anti-angiogenic agent fumagillin is shown, along with its derivative, TNP-470
(16). Reprinted with permission.
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Figure 2. Overall structure of MetAP-2 bound to fumagillin. MetAP-2 (shown

in red, green, light blue) is characterized by 7 a helices and 9 (3 sheets.
Fumagillin (shown in yellow and red ball and stick) binds in the active site of
the enzyme. The two cobalt molecules (shown in dark blue) are partially
obstructed by fumagillin (25). Reprinted with permission.
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Figure 3. Fumagillin binding causes a conformational change in H339. A
portion of the active site of native MetAP-2 is shown in blue. Fumagillin
(black and red) bound to MetAP-2 is shown in yellow. A conformational
change takes place, shifting the position of the imidazole side chain of
His339). Other close contacts are labeled using the one letter amino acid code
and a number indicating position in the primary structure. (Figure generated
with the assistance of Mark Briedenbach).
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Figure 4. Fumagillin in the active site of MetAP-2. Fumagillin and the
covalently attached His231 are shown as ball and stick with carbon yellow,
oxygen red, and nitrogen blue. Side chains that interact with fumagillin are
drawn as sticks, either in green (native protein) or blue (drug-bound protein)
(25). Reprinted with permission.
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Figure 5. Close side chain contacts to fumagillin in the binding pocket of
MetAP-2. Black dashed lines indicate hydrogen bonds, red radial lines indicate
hydrophobic contacts. Wat= water molecule, Co= cobalt molecule (25).
Reprinted with permission.
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Figure 6. Site-Directed Mutagenesis. Template DNA containing the desired
target gene is shown. A primer is designed containing the desired mismatch.
The PCR reaction is carried out, using the plasmid as a template. The original
DNA is digested using Dpn I, leaving only the synthesized DNA containing
the desired mutation. DH5-a competent bacteria were used in this study.
Figure reproduced from Stratagene QuickChange Site Directed Mutagenesis
Manual.
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Mutation
F219I
F219W
Y444I
Y444W
G341D
G341S
G341V
G341A
G341H
H339F

Forward (51 to3') Primer
gga gga tcc caa ate tea agg tat tgg gat tcc aac ggg tet c
gga gga tcc caa ate tea agg tat tgg gtg gee aac ggg tet c
egg ttt agt aca gga tat tcc ace att gaa ega tat ccc egg
egg ttt agt aca gga ttg gee ace att gaa ega tat ccc egg
c gca cca tat cgt ate cac ggc gat aaa tcc gtt ccc
c gca cca tat cgt ate cac ggc agt aaa tcc gtt ccc
gca cca tat cgt ate cac ggc gtt aaa tcc gtt ccc ate
gca cca tat cgt ate cac ggc get aaa tcc gtt ccc ate
gca cca tat cgt ate cac ggc cat aaa tcc gtt ccc ate
gta teg cac cat ate gta tet teg geg gta aat ccg

Figure 7. Primers used in Site Directed Mutagenesis. Forward (5' to 3 )
sequence of the primer used in site directed mutagenesis are listed. Reverse
primers used are the reverse complements of the sequences listed above.
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Mutation

Trp-

Fg

F219I
F219W
Y444I
Y444W
G341D
G341S
G341V
G341A
G341H
H339F

+
+
+
+
+
+
+
+
+
+

0
0
0
0
lOnM
5nM
0
0
0
InM

Figure 8. Growth of test mutations on fumagillin. Mutations tested are listed.
The second column (Trp-) indicates growth on tryptophan dropout plates.
The third column (Fg) indicates the highest concentration of fumagillin on
which the strain grew.
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